文献速递免疫规划传染病防控与疫情报告

2024-2025年BNT162b2 KP.2新冠疫苗接种后不良事件监测

Monitoring of adverse events following 2024-2025 BNT162b2 KP.2 COVID-19 vaccination in the United States.
PubMed 文献 · Vaccine · 2026-10-26

本研究在美国商业保险人群中监测2024-2025年BNT162b2 KP.2新冠疫苗接种后20种特别关注不良事件(AESI)。采用自身对照风险区间设计,纳入894,852名≥6月龄接种者(中位年龄46.9岁),比较接种后风险期与后续对照期的AESI发生率。未发现安全信号,但研究对罕见结局把握度不足。

要点

  • 接种后风险期非热性惊厥/癫痫相对发生率1.29(95%CI 0.92-1.81),无统计学意义。
  • 带状疱疹相对发生率1.05(95%CI 0.59-1.85),无统计学意义。
  • 未发现2024-2025年BNT162b2 KP.2疫苗安全信号,但对罕见结局把握度不足。

核心结论

  • 在美國商业保险人群中,接种2024-2025年BNT162b2 KP.2新冠疫苗后未发现安全信号。
  • 研究对罕见结局的统计把握度不足。

研究设计与样本

  • 自身对照风险区间设计,比较接种后风险期与后续对照期的20种AESI发生率。
  • 纳入2024年8月22日至2025年3月10日接种的≥6月龄个体894,852人(中位年龄46.9岁),数据来自Optum预裁决数据库。

主要发现

  • 非热性惊厥/癫痫相对发生率1.29(95%CI 0.92-1.81),风险期点估计高于对照期但无统计学意义。
  • 带状疱疹相对发生率1.05(95%CI 0.59-1.85),风险期点估计高于对照期但无统计学意义。

临床怎么用

  • 监测结果支持2024-2025年BNT162b2 KP.2新冠疫苗在商业保险人群中的安全性,但罕见不良事件需持续监测。

局限性

  • 研究对罕见结局的统计把握度不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Large real-world data studies are needed to understand the safety profile of the 2024-2025 adapted COVID-19 vaccines. This study monitors the occurrence of 20 adverse events of special interest (AESIs) following 2024-2025 BNT162b2 KP.2 COVID-19 vaccination. Individuals age ≥ 6 months vaccinated between 08/22/2024 and 03/10/2025 were identified within the Optum pre-adjudicated database. A self-controlled risk interval design was used to compare the incidence of 20 AESIs during a risk period following vaccination to a subsequent control period among 894,852,024-2025 BNT162b2 COVID-19-vaccinated individuals (median age: 46.9 years). While point estimates were higher in the risk period compared to the control period for non-febrile convulsions/seizures (relative incidence: 1.29; 95% CI: 0.92-1.81) and herpes zoster (relative incidence: 1.05; 95% CI: 0.59-1.85), the magnitude was not significant. No safety signals were identified following 2024-2025 BNT162b2 COVID-19 vaccination among commercially insured individuals in the United States, though the study was underpowered for rare outcomes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sun JW, Dodge LE, Cai S, et al. Monitoring of adverse events following 2024-2025 BNT162b2 KP.2 COVID-19 vaccination in the United States. Vaccine. 2026. PMID: 42933241. doi:10.1016/j.vaccine.2026.129296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。